C14orf50 Inhibitors
Inhibitors of C14orf50 exploit several biochemical mechanisms to diminish the functional activity of this protein, targeting the molecular signaling pathways it is involved in. Kinase inhibitors, for instance, disrupt the phosphorylation events essential for the proper signaling through pathways that C14orf50 is implicated in, effectively diminishing its activity. Similarly, when molecules inhibit the PI3K/Akt pathway, a critical cell survival and proliferation route, the activity of downstream proteins like C14orf50 is suppressed due to the lack of essential survival and growth signals. Certain inhibitors also target the mTOR pathway, which is instrumental in cell growth and metabolism, leading to a reduction in C14orf50 activity as a result of attenuated mTOR signaling.
Additional inhibitors focus on the MAP kinase pathways, such as the MEK/ERK and p38 MAPK, which are integral to the regulation of cell division, growth, and stress responses. By obstructing these pathways, the inhibitors effectively reduce the signaling that would activate C14orf50. Moreover, proteasome inhibitors can indirectly decrease C14orf50 activity by interfering with the degradation of regulatory proteins that may control its function. Furthermore, tyrosine kinase inhibitors and EGFR pathway blockers can suppress the activity of C14orf50 if it is regulated by these pathways, preventing the initiation of the signaling cascades C14orf50 is part of. Lastly, inhibitors that target Aurora kinase impact cell cycle regulation, reducing the function of C14orf50 assuming its activity is linked to this process.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. C14orf50, being a part of specific kinase signaling pathways, would see its activity reduced due to the downstream effects of kinase inhibition that staurosporine provides. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. Given that C14orf50 is involved in PI3K/Akt signaling, the inhibition of PI3K would prevent the activation of downstream targets, thereby inhibiting the functional activity of C14orf50. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. Since C14orf50 functions within the mTOR signaling pathway, its activity would be decreased as rapamycin inhibits mTOR, leading to reduced activation of downstream components that C14orf50 influences. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor. It interferes with the MEK/ERK pathway, which may be implicated in the regulation of C14orf50. The inhibition of MEK leads to a reduction in ERK-mediated processes that C14orf50 is a part of. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, the stress-activated protein kinase pathway is downregulated, which would decrease C14orf50 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. It prevents the degradation of proteins involved in cell cycle regulation, leading to decreased function of C14orf50. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a covalent inhibitor of PI3K. By inhibiting PI3K, it would block the PI3K/Akt pathway and subsequently decrease the activity of C14orf50. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is a JNK inhibitor. It would inhibit the JNK signaling pathway, which may affect C14orf50 activity given C14orf50 is involved in JNK-mediated cellular processes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor. It specifically targets certain tyrosine kinases, which would lead to decreased C14orf50 activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor. Assuming C14orf50 is involved in the EGFR signaling pathway, gefitinib would decrease its activity by inhibiting the pathway's initial receptor-ligand interaction and subsequent intracellular signaling. | ||||||